

**Aquaporin-4 head-to-head studies**

| Study ID   |              |      | Live CBA    |              |              |             |              |              | Fixed CBA   |              |              |             |              |              | Cohort |     |
|------------|--------------|------|-------------|--------------|--------------|-------------|--------------|--------------|-------------|--------------|--------------|-------------|--------------|--------------|--------|-----|
| Study PMID | First Author | Year | Sensitivity | 95% CI lower | 95% CI upper | Specificity | 95% CI lower | 95% CI upper | Sensitivity | 95% CI lower | 95% CI upper | Specificity | 95% CI lower | 95% CI upper | TP     | TN  |
| 24223884   | Höftberger   | 2013 | 100.0       | 95.4         | 100.0        | 100.0       | 97.5         | 100.0        | 97.4        | 91.0         | 99.7         | 100.0       | 97.5         | 100.0        | 78     | 147 |
| 27113605   | Waters       | 2016 | 100.0       | 94.6         | 100.0        | 97.6        | 93.3         | 99.5         | 92.4        | 83.2         | 97.5         | 100.0       | 97.1         | 100.0        | 66     | 127 |
| 27658059   | Yang         | 2016 | 98.2        | 93.4         | 100.0        | 100.0       | 97.9         | 100.0        | 78.2        | 68.6         | 90.8         | 99.1        | 97.9         | 100.0        | 55     | 111 |
| 31636597   | Prain        | 2019 | 97.0        | 84.2         | 99.9         | 100.0       | 96.6         | 100.0        | 100.0       | 89.4         | 100.0        | 99.1        | 95.0         | 100.0        | 33     | 108 |
| 39901660   | Said         | 2025 | 97.3        | 90.6         | 99.7         | 100.0       | 99.3         | 100.0        | 71.6        | 60.0         | 81.5         | 100.0       | 99.3         | 100.0        | 74     | 503 |
| Totals     |              |      | 98.7        | 96.7         | 99.6         | 99.7        | 99.1         | 99.9         | 86.9        | 82.6         | 90.5         | 99.8        | 99.3         | 100.0        | 306    | 996 |

**MOG head-to-head studies**

| Study ID   |              |      | Live CBA    |              |              |             |              |              | Fixed CBA   |              |              |             |              |              | Cohort |      |
|------------|--------------|------|-------------|--------------|--------------|-------------|--------------|--------------|-------------|--------------|--------------|-------------|--------------|--------------|--------|------|
| Study PMID | First Author | Year | Sensitivity | 95% CI lower | 95% CI upper | Specificity | 95% CI lower | 95% CI upper | Sensitivity | 95% CI lower | 95% CI upper | Specificity | 95% CI lower | 95% CI upper | TP     | TN   |
| 31481127   | Tea          | 2019 | 100.0       | 97.3         | 100.0        | 100.0       | 97.5         | 100.0        | 64.4        | 55.8         | 72.5         | 100.0       | 92.5         | 100.0        | 135    | 47   |
| 30728305   | Waters       | 2019 | 100.0       | 86.3         | 100.0        | 100.0       | 99.0         | 100.0        | 92.0        | 74.0         | 99.0         | 98.6        | 99.0         | 100.0        | 25     | 369  |
| 31954354   | Tzartos      | 2020 | 100.0       | 83.9         | 100.0        | 100.0       | 97.5         | 100.0        | 85.7        | 63.7         | 97.0         | 100.0       | 97.5         | 100.0        | 21     | 148  |
| 32024795   | Reindl       | 2020 | 100.0       | 91.0         | 100.0        | 100.0       | 91.2         | 100.0        | 84.6        | 69.5         | 94.1         | 97.5        | 86.8         | 99.9         | 39     | 40   |
| 32623596   | Gastaldi     | 2020 | 94.7        | 82.3         | 99.4         | 97.0        | 83.3         | 99.9         | 89.5        | 75.2         | 97.1         | 97.0        | 83.3         | 99.9         | 38     | 33   |
| 33510701   | Cross        | 2020 | 85.7        | 63.7         | 97.0         | 99.3        | 96.1         | 99.9         | 33.3        | 14.6         | 57.0         | 100.0       | 97.4         | 100.0        | 21     | 145  |
| 37665286   | Seok         | 2024 | 100.0       | 69.2         | 100.0        | 100.0       | 97.7         | 100.0        | 90.0        | 55.5         | 99.8         | 98.1        | 94.5         | 99.6         | 10     | 156  |
| 39901660   | Said         | 2025 | 95.1        | 87.8         | 98.6         | 97.7        | 96.0         | 98.8         | 45.7        | 34.6         | 57.1         | 99.8        | 98.9         | 100.0        | 81     | 513  |
| 40878871   | Vij          | 2025 | 100.0       | 66.4         | 100.0        | 95.8        | 88.1         | 99.1         | 44.4        | 13.7         | 78.8         | 95.8        | 88.1         | 99.1         | 9      | 71   |
| Totals     |              |      | 97.6        | 95.5         | 98.9         | 98.9        | 98.2         | 99.35        | 66.5        | 61.49        | 71.23        | 99.1        | 98.46        | 99.5         | 369    | 1366 |

TP: True Positives - any positive result in the clinically defined NMOSD or MOGAD or considered meeting published criteria. TN: True Negative - any individual not meeting criteria or considered controls